Medicus Pharma Ltd. Common Stock (MDCX)
Automate Your Wheel Strategy on MDCX
With Tiblio's Option Bot, you can configure your own wheel strategy including MDCX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MDCX
- Rev/Share 0.0
- Book/Share 0.1754
- PB 20.7184
- Debt/Equity 0.1372
- CurrentRatio 1.5252
- ROIC -5.9473
- MktCap 49336899.0
- FreeCF/Share -1.063
- PFCF -3.7919
- PE -4.7516
- Debt/Assets 0.0521
- DivYield 0
- ROE -2.4601
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering
Published: May 29, 2025 by: Newsfile Corp
Sentiment: Neutral
Philadelphia, Pennsylvania--(Newsfile Corp. - May 29, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its public offering of 2,260,000 units, on a "best-efforts" basis, at a price of $3.10 per unit.
Read More
Medicus Pharma gets UAE approval for Phase 2 study for skin cancer therapy
Published: May 22, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) has received regulatory approval from the UAE Department of Health to begin a Phase 2 clinical trial evaluating its non-invasive therapy for basal cell carcinoma (BCC) of the skin. The study, designated SKNJCT-004, will enroll up to 36 patients across four medical centers in the UAE.
Read More
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
Published: May 22, 2025 by: Newsfile Corp
Sentiment: Neutral
The Clinical Study Is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAE Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce that it has received study may proceed approval from the UAE DOH to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat BCC of the skin.
Read More
Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio
Published: May 12, 2025 by: Benzinga
Sentiment: Positive
In April, Medicus Pharma Ltd. MDCX agreed to acquire all of Antev's issued and outstanding shares on a share exchange.
Read More
Medicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatment
Published: April 28, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) announced that it has entered into a binding letter of intent to acquire Antev, a clinical-stage biotechnology firm developing a first-in-market product Teverelix for acute urinary retention (AUR) and high cardiovascular risk prostate cancer. Teverelix, a next-generation GnRH antagonist, targets the prevention of recurrent AUR in males aged 45 years and older with benign prostate hyperplasia.
Read More
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.
Published: April 28, 2025 by: Newsfile Corp
Sentiment: Neutral
Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments Antev is developing Teverelix, A next generation GnRH Antagonist, as first in class market product for Acute Urinary Retention (AUR) and high CV risk Prostate Cancer Philadelphia, Pennsylvania--(Newsfile Corp. - April 28, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd.
Read More
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Published: April 21, 2025 by: Newsfile Corp
Sentiment: Neutral
The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe Philadelphia, Pennsylvania--(Newsfile Corp. - April 21, 2025) - Medicus Pharma Ltd.
Read More
Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results
Published: March 06, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX) has revealed interim results from its Phase 2 clinical trial for a non-invasive treatment targeting basal cell carcinoma (BCC) showing promising efficacy and safety outcomes. An interim analysis on the ongoing study, carried out after more than half of the patients were randomized, indicated that over 60% of subjects achieved complete clinical clearance of BCC.
Read More
Medicus Pharma expects interim data from Phase 2 skin cancer trial by quarter-end
Published: February 14, 2025 by: Proactive Investors
Sentiment: Positive
Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) has announced progress in its Phase 2 clinical study SKNJCT-003, which is evaluating its investigational drug D-MNA in basal cell carcinoma (BCC). The company said that the trial, currently underway at nine clinical sites in the United States, has now randomized more than 50% of the 60 patients expected to be enrolled.
Read More
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Published: February 14, 2025 by: Newsfile Corp
Sentiment: Neutral
The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) Philadelphia, Pennsylvania--(Newsfile Corp. - February 14, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003), which is currently underway in nine (9) clinical sites in United States, has now randomized more than 50% of the 60 patients expected to be enrolled in the study.
Read More
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
Published: February 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
The company is on track to complete the interim data analysis before the end of Q1 2025 and to submit the findings to the U.S. Food And Drug Administration (FDA) The company is on track to complete the interim data analysis before the end of Q1 2025 and to submit the findings to the U.S. Food And Drug Administration (FDA)
Read More
Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
Published: February 11, 2025 by: Newsfile Corp
Sentiment: Neutral
Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2025) - Medicus Pharma Ltd.
Read More
Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital Market
Read More
About Medicus Pharma Ltd. Common Stock (MDCX)
- IPO Date 2024-11-15
- Website https://medicuspharma.com/
- Industry Biotechnology
- CEO Dr. Raza Bokhari M.B.A., M.D., MBA
- Employees None